Vaccine maker Astrazeneca set to build on solid 2020 results
Pharmaceuticals giant Astrazeneca produced strong results for 2020, and predicted a "low teens percentage" boost for revenues in the current financial year.
Total revenues rose 10% on constant exchange rates to $26.617bn, while pre-tax profits jumped from $1.548bn to $3.916bn, helped by progress in new medicines.
Astrazeneca, which employs around 4,700 people in the North West on sites at Macclesfield and Alderley Park in Cheshire and Speke on Merseyside, developed the COVID-19 vaccine C19VAZ in collaboration with the University... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
